Barrington analyst Michael Petusky maintained a Buy rating on Anika Therapeutics Inc (ANIK – Research Report) today and set a price target of $60.00. The company’s shares closed last Monday at $68.67, close to its 52-week high of $70.75.
According to TipRanks.com, Petusky is a 3-star analyst with an average return of 2.9% and a 49.4% success rate. Petusky covers the Healthcare sector, focusing on stocks such as Varian Medical Systems, Merit Medical Systems, and DENTSPLY SIRONA Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Anika Therapeutics Inc with a $60.00 average price target.
Anika Therapeutics Inc’s market cap is currently $748M and has a P/E ratio of 26.42. The company has a Price to Book ratio of 2.98.
Based on the recent corporate insider activity of 17 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ANIK in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Anika Therapeutics, Inc. is an orthopedic and regenerative medicines company, which develops, manufactures and commercializes therapeutic products for pain management, tissue regeneration, and wound healing. Its products are based on hyaluronic acid, a natural chemical occurring, biocompatible polymer found throughout the body.